Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
https://doi.org/10.14341/DM9623
Abstract
Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications. At the same time, weight loss can reduce the risk of type 2 diabetes in obese and pre-diabetic patients. According to available data, a significant decrease in the incretin effect is observed in patients with type 2 diabetes and obese individuals. Thus, a decrease in the incretin effect leads to a violation of the insulin response to the intake of carbohydrates, and, consequently, an increase in the level of glucose in the blood. It was also found that the decrease in the incretin effect in patients with type 2 diabetes can be associated with a lower secretion of glucagon-like peptide-1. The interest is represented by groups of antidiabetic drugs capable of regulating glycemia by affecting the secretion of insulin and glucagon, depending on its level. Such drugs include glucagon-like peptide-1 receptor agonists.
The article shows the advantage of prolonged action in patients with type 2 diabetes and obesity of the glucagon-like peptide 1 receptor agonists (albiglutide, dulaglutide, exenatide with slow release) dosing 1 time a week.
About the Authors
Nina A. PetuninaI.M. Sechenov First Moscow State Medical University
Russian Federation
MD, PhD, Professor
Milena Е. Telnova
I.M. Sechenov First Moscow State Medical University
Russian Federation
MD, PhD, assistant lecturer
References
1. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. / Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. – 8-й выпуск // Сахарный диабет. – 2017. – Т. 20. – №1S. – C. 1-121.[Dedov II, Shestakova MV, Mayorov AY, et al. Dedov II, Shestakova MV, Mayorov AY, editors. Standards of specialized diabetes care. 8th edition. Diabetes mellitus. 2017; 20(1S):1-121. (In Russ.)] doi: 10.14341/DM20171S8
2. Dengo AL, Dennis EA, Orr JS, et al. Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension. 2010;55(4):855-861. doi: 10.1161/HYPERTENSIONAHA.109.147850
3. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-1789. doi: 10.1016/s0140-6736(08)60766-7
4. Hu G, Lindstrom J, Valle TT, et al. Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med. 2004;164(8):892-896. doi: 10.1001/archinte.164.8.892
5. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006;116(7):1756-1760. doi: 10.1172/JCI29189
6. Freemantle N, Holmes J, Hockey A, Kumar S. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract. 2008;62(9):1391-1396. doi: 10.1111/j.1742-1241.2008.01805.x
7. Lebovitz HE, Banerji MA. Point: Visceral Adiposity Is Causally Related to Insulin Resistance. Diabetes Care. 2005;28(9):2322-2325. doi: 10.2337/diacare.28.9.2322
8. Hu G, Lindstrom J, Valle TT, et al. Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med. 2004;164(8):892-896. doi: 10.1001/archinte.164.8.892
9. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi: 10.1056/NEJMoa012512
10. Мкртумян А.М. Ликсисенатид – прандиальный агонист рецептора глюкагоноподобного пептида-1 // Эффективная фармакотерапия. – 2015. – №32. – С. 16-22. [Mkrtumyan AM. Lixisenatide – a Prandial Glucagon-Like Peptide-1 Receptor Agonist. Effektivnaya farmakoterapiya. 2015;(32):16-22. (In Russ.)
11. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. Практическое руководство для врачей. – М.; 2010. [Dedov II, Shestakova MV. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-tipa. A practical guide for physicians. Moscow; 2010. (In Russ.)]
12. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340-1348. doi: 10.2337/db07-1315
13. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2014;16(1):9-21. doi: 10.1111/dom.12119
14. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology. 2009;150(4):1680-1687. doi: 10.1210/en.2008-1045
15. Herrmann C, Goke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56(2):117-126. doi: 10.1159/000201231
16. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48(4):612-615. doi: 10.1007/s00125-005-1705-7
17. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. doi: 10.1053/j.gastro.2007.03.054
18. Тельнова М.Э., Петунина Н.А. Оценка показателя уровня глюкогоноподобного пептида-1 при ожирении базально и в ходе теста с пищевой нагрузки // Медицинский вестник МВД. – 2014. – №4. – С. 41-45. [Telnova ME, Petunina NA. Evaluation of glucagon-like peptide-1 level indicator in persons with obesity basal and in the courseof alimentary load. Meditsinskiy vestnik MVD. 2014;(4):41-45. (In Russ.)]
19. Rodriquez de Fonseca F, Navarro M, Alvarez E, et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism. 2000;49(6):709-717. doi: 10.1053/meta.2000.6251
20. Knop FK, Aaboe K, Vilsboll T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab. 2012;14(6):500-510. doi: 10.1111/j.1463-1326.2011.01549.x
21. Adam TCM, Westerterp-Plantenga MS. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr. 2007;93(06):845. doi: 10.1079/bjn20041335
22. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723. doi: 10.1210/jcem.86.8.7750
23. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88(6):2706-2713. doi: 10.1210/jc.2002-021873
24. Flint A, Raben A, Rehfeld JF, et al. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes. 2000;24(3):288-298. doi: 10.1038/sj.ijo.0801126
25. Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia. 2012;55(7):1890-1901. doi: 10.1007/s00125-012-2556-7
26. American Diabetes Assotiation. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2017;40(Suppl 1):S64-S74. doi: 10.2337/dc17-S011
27. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary. Endocr Pract. 2016;22(1):84-113. doi: 10.4158/EP151126.CS
28. grls.rosminzdrav.ru [интернет]. Государственный реестр лекарственных средств [доступ от 14.09.2018]. Доступ по ссылке: http://grls.rosminzdrav.ru/default.aspx. [Grls.rosminzdrav.ru [Internet]. State Register of Medicines [cited 2018 Sep 14]. Available from: http://grls.rosminzdrav.ru/Default.aspx. (In Russ.)]
29. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2-3):58-64. doi: 10.1016/j.regpep.2010.05.008
30. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration. J Med Chem. 2000;43(9):1664-1669. doi: 10.1021/jm9909645
31. Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015;49(3):351-359. doi: 10.1177/1060028014564180
32. Ema.europa.eu [Internet]. Bydureon. Summary of product characteristics [cited 2018 Sep 14]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/huma n/002020/WC500108241.pdf.
33. rlsnet.ru [интернет]. Баета Лонг [доступ от 14.09.2018]. Доступ по ссылке: https://www.rlsnet.ru/tn_index_id_94925.htm. [Rlsnet.ru [Internet]. Byetta Long [cited 2018 Sep 14]. Available from: https://www.rlsnet.ru/tn_index_id_94925.htm. (In Russ.)]
34. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771
35. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447-1456. doi: 10.1016/s0140-6736(10)60307-8
36. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. doi: 10.1016/s0140-6736(12)61267-7
37. Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17(11):1065-1074. doi: 10.1111/dom.12541
38. Галстян Г.Р., Каратаева Е.А., Юдович Е.А. Эволюция агонистов рецепторов глюкагоноподобного пептида-1 в терапии сахарного диабета 2 типа // Сахарный диабет. – 2017. – Т. 20. – №4. – С. 286-298. [Galstyan GR, Karataeva EA, Yudovich EA. Evolution of glucagon-like peptide-1 receptor agonists for type 2 diabetes treatment. Diabetes mellitus. 2017;20(4):286-298. (In Russ.)] doi: 10.14341/DM8804
39. Xue X, Ren Z, Zhang A, et al. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials. Int J Clin Pract. 2016;70(8):649-656. doi: 10.1111/ijcp.12847
40. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310. doi: 10.1210/jc.2010-2081
41. Wong C, Fisher M. Inconclusive effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. Practical Diabetes. 2017;34(9):302-303. doi: 10.1002/pdi.2140
42. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823-830 e825. doi: 10.1016/j.ahj.2013.07.012
43. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141
44. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocr Pract. 2018;24(1):91-120. doi: 10.4158/CS-2017-0153
Supplementary files
|
|
1. Fig. 1. Primary and secondary endpoints (EXSCEL study). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(146KB)
|
Indexing metadata ▾ | |
Review
For citations:
Petunina N.A., Telnova M.Е. Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes. Diabetes mellitus. 2018;21(4):293-300. (In Russ.) https://doi.org/10.14341/DM9623
Views:
6060
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
